Fujirebio Revenue
Biotechnology Research • 
Ghent, Flemish Region, Belgium • 501-1000 Employees
Fujirebio revenue & valuation
| Annual revenue | $59,000,000 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $188,700,000 |
| Total funding | No funding |
Key Contact at Fujirebio
Company overview
| Headquarters | Technologiepark 6, Gent, 9052, BE |
| Website | |
| NAICS | 541714 |
| SIC | 283 |
| Keywords | Molecular Biology, Genetic Testing, OEM, Multiple Sclerosis, Parkinson'S Disease, Thyroid, In Vitro Diagnostics, IVD, Fertility, Infectious Diseases, Cdmo, Molecular Diagnostics, Virology, Neurodegeneration, Immunoassays, HPV, Alzheimer'S Disease, Bone Testing, Multiparameter Testing, Strip-Based Diagnostics, Tissue Typing, Tumour Markers, Dna Methylation, Line Immunoassays |
| Founded | 1950 |
| Employees | 501-1000 |
| Socials |
Fujirebio Email Formats
Fujirebio uses 4 email formats. The most common is {first name}.{last name} (e.g., john.doe@fujirebio.com), used 82.5% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name} | john.doe@fujirebio.com | 82.5% |
{first initial}.{last name} | j.doe@fujirebio.com | 12.4% |
{2char} | {2char}@fujirebio.com | 4.1% |
{first initial}.{second initial} | j.o@fujirebio.com | 1% |
About Fujirebio
Fujirebio is a global leader in the field of high-quality in vitro diagnostics (IVD). We are an R&D-driven company constantly developing new technologies and unique biomarkers with high clinical value. Our group mission is to create new value in healthcare and thereby contribute to human health and the future of medical care. Our global teams located in Japan, Asia, Europe and the US focus on delivering products with the highest quality standards to our customers and partners. We value partnerships with other leading companies in the industry, sharing knowledge, capabilities, and critical materials in order to supply, develop or manufacture diagnostic solutions on a wide variety of platforms. Through this business model, we ensure that the potentially life-changing diagnostic markers meet the largest global need in the shortest possible time. Fujirebio has a strong and long-lasting tradition of collaborating with experts in the worldwide clinical community in the development of high-quality routine and truly novel biomarkers that cover a variety of disease states. Its IVD product lines span the range from specialized manual and automated testing to fully automated routine clinical laboratory testing solutions. Founded in 1950 in Tokyo, Japan, Fujirebio has over the years concluded a number of successful acquisitions of best-in-class IVD companies. Examples include Centocor Diagnostics in 1998, CanAg Diagnostics in 2006 and Innogenetics in 2010. Today, Fujirebio’s global presence includes offices in the United States, Latin America, Europe and Asia as well as a vast international distribution network. Fujirebio is today a consolidated subsidiary of H.U. Group Holdings, Inc. (listed on the Tokyo Stock Exchange – TYO: 4544) and employs more than 1,200 people in Asia, Europe and America.
Employees by Management Level
Total employees: 501-1000
Seniority
Employees
Employees by Department
Fujirebio has 338 employees across 16 departments.
Departments
Number of employees
Funding Data
Fujirebio has never raised funding before.
Fujirebio Tech Stack
Discover the technologies and tools that power Fujirebio's digital infrastructure, from frameworks to analytics platforms.
Security
JavaScript libraries
Miscellaneous
CMS
JavaScript libraries
Maps
Video players
Web servers
Marketing automation
JavaScript libraries
United States
Italy
United Arab Emirates
Canada
Germany
Spain
Frequently asked questions
4.8
40,000 users
